A quick peek into the report
Table of Contents
Overview
2.1 Market Drivers
2.1.1 Growing Prevalence of Non-Communicable Diseases is Boosting the Demand for Advanced Life Science Tools
2.1.2 Increasing Government Initiatives to Boost Life Sciences Sector
2.1.3 Increased Biomedical Research amid COVID-19 Pandemic in the Middle East
2.1.4 Increasing Aceptance of Precision and Medicine in Middle East
2.1.5 Local Manufacturing will Support the Growth of Life Sciences in the Middle East
2.2 Market Restraints
2.2.1 Dearth of Skilled Professionals in the Middle East
2.2.1 Lack of Adoption of Healthcare Solutions and Equipment in Laboratories
COVID-19 Impact
4.1 By Product
4.2 By Application
4.3 By End User
4.4 Competitive Landscape
4.5 Thermo Fisher Position in the Market
5.1 By Product
5.2 By Application
5.3 By End User
5.4 Competitive Landscape
5.5 Thermo Fisher Position in the Market
6.1 By Product
6.2 By Application
6.3 By End User
6.4 Competitive Landscape
6.5 Thermo Fisher Position in the Market
7.1 By Product
7.2 By Application
7.3 By End User
7.4 Competitive Landscape
7.5 Thermo Fisher Position in the Market
8.1 By Product
8.2 By Application
8.3 By End User
8.4 Competitive Landscape
8.5 Thermo Fisher Position in the Market
9.1 By Product
9.2 By Application
9.3 By End User
9.4 Competitive Landscape
9.5 Thermo Fisher Position in the Market
Middle East Life Sciences Market Overview
Middle East PCR Market |
|||
Base Year |
2021 |
Market Size in 2022 |
$306.0 Million |
Forecast Period |
2022-2032 |
Value Projection and Estimation by 2032 |
$813.1 Million |
CAGR During Forecast Period |
10.27% |
|
|
Middle East RT-PCR Market |
|||
Base Year |
2021 |
Market Size in 2022 |
$163.9 Million |
Forecast Period |
2022-2032 |
Value Projection and Estimation by 2032 |
$596.2 Million |
CAGR During Forecast Period |
13.78% |
|
|
Key Questions Answered in the Report
• What is the growth potential of various life science technologies including PCR, d-PCR, RT-PCR, NGS, Cell Culture and Western Blotting in the Middle East Market?
• Who are the major players having the highest influence on the Middle East life sciences market?
• What are the major market drivers, challenges, and opportunities in the Middle East life sciences market?
• What are the underlying structures resulting in the emerging trends in the Middle East life sciences market?
• How is the COVID-19 pandemic impacting the Middle East life sciences market landscape?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region for the development of next-generation sequencing, PCR, RT-PCR, d-PCR, cell culture and western blotting?
• What is the position of Thermo Fisher Scientific, Inc. within the entire Middle East life sciences market including PCR, d-PCR, RT-CR, NGS, cell culture and western blotting?
• Which are the key developments including product launches, M&A, Collaborations and Partnerships that have taken place within the past 3 years for all the different life sciences technologies?
• What are the underlying structures resulting in the emerging trends in the Middle East life sciences market?
• What are the expert insights for scenario and adaptation of life sciences market in various countries for PCR, d-PCR, RT-CR, NGS, cell culture and western blotting?
• How is each segment of the market expected to grow during the forecast period 2022-2032, and what is the anticipated revenue to be generated by each segment?
Introduction of Middle East Life Sciences Market
Executive Summary
The Middle East has experienced substantial advancements in the life sciences industry, driven by factors such as enhanced diagnostic capabilities, increasing prevalence of chronic and acute diseases, growth in translational research, and well-established research and development (R&D) centers. The United Arab Emirates (U.A.E.) has positioned itself as the life sciences hub of the Middle East and North Africa (MENA) region. Countries like Saudi Arabia (K.S.A.), Egypt, and Turkey have rapidly growing and highly regulated life sciences industries. These nations are leveraging precision medicine and innovative solutions to improve healthcare outcomes.
The Middle East life sciences market encompasses various technologies, including polymerase chain reaction (PCR), next-generation sequencing (NGS), digital PCR (d-PCR), cell culture, and western blotting. While RT-PCR instruments are widespread in the region, NGS instruments, such as Illumina’s Novaseq and Miseq, are commonly used in population sequencing projects. However, limited skilled professionals and slow adoption of advanced healthcare solutions in some laboratories continue to pose challenges. The post-COVID-19 era has brought increased awareness of modern molecular testing techniques, further driving the market growth.
Key Market Segments
- Middle East RT-PCR Market:
- Valued at $144.5 million in 2021, projected to reach $596.2 million by 2032 with a CAGR of 13.78%.
- Widely adopted in clinical diagnostics, especially during the COVID-19 pandemic.
- Major players include G42 Healthcare and Thermo Fisher Scientific.
- Middle East PCR Market:
- Valued at $273.6 million in 2021, expected to grow to $813.1 million by 2032 at a CAGR of 10.27%.
- Conventional and RT-PCR technologies dominate this segment, supported by initiatives such as the G42-BGI collaboration for COVID-19 detection.
- Middle East d-PCR Market:
- Estimated at $15.6 million in 2021, projected to reach $73.7 million by 2032 at a CAGR of 15.19%.
- Emerging market with limited adoption in laboratories. Bio-Rad Laboratories and QIAGEN are key contributors.
- Middle East NGS Market:
- Valued at $215.6 million in 2021, expected to grow to $1,285.8 million by 2032 with a CAGR of 15.71%.
- Dominated by Illumina and Thermo Fisher Scientific, supported by regional genome projects such as the Emirati Genome Project and Qatar Genome Project.
- Middle East Cell Culture Market:
- Valued at $237.5 million in 2021, forecasted to reach $561.9 million by 2032 with a CAGR of 7.74%.
- Major players include GE Healthcare and Thermo Fisher Scientific, with applications in biopharma and academic research.
- Middle East Western Blotting Market:
- Valued at $44.9 million in 2021, projected to grow to $93.2 million by 2032 at a CAGR of 6.57%.
- Key players include Bio-Rad Laboratories and Cleaver Scientific.
- Increased Research Activities:
- Government investments in genomic and proteomic research are boosting the adoption of advanced technologies like NGS and d-PCR.
- Impact of COVID-19:
- Accelerated the adoption of RT-PCR and d-PCR technologies for viral detection and genomic surveillance.
- Growing Biopharma Sector:
- Increasing R&D activities in biopharmaceuticals are driving demand for cell culture and western blotting techniques.
- Public-Private Collaborations:
- Initiatives such as the Emirati Genome Project and Saudi Genome Project demonstrate the role of partnerships in advancing the life sciences sector.
- Digital Transformation:
- Over 57% of researchers in the region are engaged in digital innovation projects to mitigate compliance risks and improve operational efficiency.
Market Restraints
- Lack of Skilled Professionals:
- Limited availability of trained personnel to operate advanced molecular testing equipment.
- Slow Adoption of Technology:
- Delays in procurement and setup of advanced equipment due to regional logistics and supply chain challenges.
- High Cost of Equipment:
- Expensive instruments like NGS sequencers and d-PCR machines restrict accessibility to smaller labs.
- Key Players: Illumina, Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN, and GE Healthcare dominate the Middle East life sciences market.
- Strategic Developments: From 2019 to 2022, the market witnessed 19 acquisitions, 19 product launches, 7 business expansions, and 4 funding initiatives.
- Notable Collaborations: G42 Healthcare’s partnerships with Seegene, InterSystems, and BGI Group enhanced molecular diagnostic capabilities.
- United Arab Emirates (U.A.E.):
- Positioned as the life sciences capital of the Middle East.
- Hosts prominent genome projects like the Emirati Genome Project.
- Saudi Arabia:
- Focused on reducing genetic diseases through initiatives like the Saudi Genome Project.
- Prominent contributor to the biopharma and biotechnology sectors.
- Qatar:
- Home to the Qatar Genome Project, advancing population genomics.
- Egypt and Turkey:
- Emerging hubs for life sciences research, supported by growing government investments.
- Population Genomics:
- Large-scale projects like the U.A.E. Genome Project aim to map genetic diversity and improve healthcare outcomes.
- Adoption of Digital Solutions:
- Increasing use of laboratory information management systems (LIMS) and other digital tools for research and diagnostics.
- Expansion of Biopharma:
- Growth in cell culture applications and proteomics research to meet rising demand for biologics.
- Innovation in Diagnostic Technologies:
- Development of high-throughput, cost-effective diagnostic tools for widespread use in clinical setting
The Middle East life sciences market is poised for significant growth, driven by advancements in genomics, proteomics, and cell biology. With a focus on precision medicine and digital transformation, the region is set to overcome challenges related to skilled labor shortages and logistical delays. Strategic investments in public-private partnerships and infrastructure development will further solidify the Middle East’s position as a global hub for life sciences innovation.
Middle East Life Sciences Market
Focus on Polymerase Chain Reaction (PCR), Digital PCR (d-PCR), Real-Time PCR (RT-PCR), Next-Generation Sequencing (NGS), Cell Culture, and Western Blotting - Analysis and Forecast, 2022-2032